Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01703533 · ClinicalTrials.gov registry record · Phase 2
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
A Phase 2 study, sponsored by Neuren Pharmaceuticals Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT01703533: Completed Phase 2 study, sponsored by Neuren Pharmaceuticals Limited.
NCT01703533 is a Phase 2 study that has completed, run by Neuren Pharmaceuticals Limited. The registered enrollment target is 67 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01703533, a Phase 2 study, has completed, sponsored by Neuren Pharmaceuticals Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.
Primary Outcome
Incidence of adverse events (AE), including Serious adverse events (SAE), will be evaluated between the two NNZ-2566 doses and placebo. SAEs will be examined from randomization through to Day 40. AEs will be examined from dosing through to Day 40.
Interventions
- DRUG Placebo
- DRUG NNZ-2566
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
What the finished NCT01703533 record still lists
NCT01703533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01703533 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01703533 about?
NCT01703533 is a clinical study titled "A Safety Study of NNZ-2566 in Patients With Rett Syndrome". The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.
What is the current status of trial NCT01703533?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2013-03. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01703533?
The interventions under investigation include: Placebo (DRUG), NNZ-2566 (DRUG).
Who is sponsoring clinical trial NCT01703533?
This trial is sponsored by Neuren Pharmaceuticals Limited, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01703533's enrollment target sits among peer trials
67 974th of 2000 higher than 1,026 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia